Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BET inhibition
Biotech
Vyne's BET inhibitor fails phase 2 vitiligo trial, sinking stock
The bad news keeps on coming for Vyne Therapeutics’ BET inhibitor platform.
James Waldron
Jul 30, 2025 9:35am
Vyne prunes psoriasis trial, but keeps faith in BET inhibitor
Jul 2, 2025 10:33am
Vyne’s psoriasis drug hit with FDA hold over testicular toxicity
Apr 25, 2025 9:25am
Novartis' $2.9B MorphoSys bet stumbles as safety delays filing
Oct 29, 2024 6:16am
Nuvation halts BET inhibitor after considering phase 1 data
Aug 5, 2024 11:02am
Novartis only wanted pelabresib, but MorphoSys had other ideas
Apr 12, 2024 8:53am
